Simulations Plus (NASDAQ:SLP) Hits New 1-Year Low - Should You Sell?

Simulations Plus, Inc. (NASDAQ:SLP - Get Free Report)'s stock price hit a new 52-week low during trading on Wednesday . The stock traded as low as $34.00 and last traded at $34.35, with a volume of 281449 shares changing hands. The stock had previously closed at $35.06.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. William Blair reissued an "outperform" rating on shares of Simulations Plus in a report on Wednesday, January 8th. StockNews.com upgraded shares of Simulations Plus from a "sell" rating to a "hold" rating in a research report on Monday, April 28th. Finally, KeyCorp lifted their price objective on Simulations Plus from $32.00 to $40.00 and gave the company an "overweight" rating in a report on Wednesday, April 16th. Two analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Simulations Plus has an average rating of "Moderate Buy" and a consensus price target of $50.00.

Simulations Plus Stock Performance

The stock has a 50-day moving average price of $28.71 and a 200-day moving average price of $30.34. The stock has a market cap of $605.84 million, a P/E ratio of 75.29 and a beta of 1.10.

Simulations Plus (NASDAQ:SLP - Get Free Report) last posted its earnings results on Thursday, April 3rd. The technology company reported $0.31 EPS for the quarter, topping analysts' consensus estimates of $0.25 by $0.06. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The business had revenue of $22.43 million during the quarter, compared to analyst estimates of $21.93 million. During the same quarter last year, the company earned $0.20 EPS. The company's quarterly revenue was up 22.5% compared to the same quarter last year. Sell-side analysts forecast that Simulations Plus, Inc. will post 1.09 earnings per share for the current fiscal year.

Insider Activity

In other news, Director Walter S. Woltosz sold 20,000 shares of the stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $33.51, for a total transaction of $670,200.00. Following the transaction, the director now owns 3,344,157 shares in the company, valued at $112,062,701.07. This trade represents a 0.59 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 19.40% of the company's stock.

Institutional Investors Weigh In On Simulations Plus

A number of large investors have recently made changes to their positions in the stock. Fifth Third Bancorp increased its holdings in Simulations Plus by 33.8% during the 1st quarter. Fifth Third Bancorp now owns 1,485 shares of the technology company's stock worth $36,000 after purchasing an additional 375 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Simulations Plus by 4.4% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,103 shares of the technology company's stock valued at $254,000 after buying an additional 380 shares during the period. Jones Financial Companies Lllp increased its holdings in Simulations Plus by 53.6% in the fourth quarter. Jones Financial Companies Lllp now owns 1,223 shares of the technology company's stock valued at $34,000 after buying an additional 427 shares in the last quarter. Pitcairn Co. boosted its position in Simulations Plus by 10.8% during the fourth quarter. Pitcairn Co. now owns 7,310 shares of the technology company's stock worth $204,000 after purchasing an additional 711 shares in the last quarter. Finally, US Bancorp DE lifted its stake in Simulations Plus by 14.3% in the 4th quarter. US Bancorp DE now owns 5,687 shares of the technology company's stock valued at $159,000 after buying an additional 713 shares in the last quarter. 78.08% of the stock is currently owned by hedge funds and other institutional investors.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.